SHOP-T 0.77 SU-T -0.49 ATD-T 0.21 CNQ-T -0.5 GOOG-Q -0.6 TTNDY-OTC 0 NOG-N -0.18
CloudMD (DOC-X)

CloudMD (DOC-X)

212 watching

CVE:DOC

0.04
0.00 (0.00%) 1d
Jul 10, 2024, 3:27 pm
0

Related posts

Nervous markets await Nvidia
DON'T BUY

CloudMD(DOC-X)

Jul 04, 2023

Did very well during the pandemic, a market darling then. But their acquisitions didn't make sense to him and they have caught up with them with poor integration. The hype is over and shares have plunged since 2020.

Jordan ZinbergJordan Zinberg
No
Unlock Rating
$0.145

Stock price when the opinion was issued

Healthcare
HOLD

CloudMD(DOC-X)

Feb 03, 2023

Tele-health company.
Has sold shares. Very high valuations.
Path to profitability slower than expected.
Recently selling assets.
Not sure path to profitability. 

Jordan ZinbergJordan Zinberg
No
Unlock Rating
$0.215

Stock price when the opinion was issued

Healthcare
WATCH

CloudMD(DOC-X)

Nov 16, 2022
Interesting story, 70M market cap. Took goodwill impairment of 84M, as a result of acquisitions. Follows it, great business model. Difficult investing environment right now. (Analysts’ price target is $0.48)
Kim BoltonKim Bolton
No
Unlock Rating
$0.230

Stock price when the opinion was issued

Healthcare
PAST TOP PICK

CloudMD(DOC-X)

Jul 14, 2022
(A Top Pick Sep 20/21, Down 76%) Whole sector decimated. One of the fastest-growing healthcare technology solutions providers. Still integrating acquisitions. Positive EBITDA has been pushed out. Management turnover. Well managed, but a show-me story.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
No
Unlock Rating
$0.380

Stock price when the opinion was issued

Healthcare
TRADE

CloudMD(DOC-X)

Jul 11, 2022
The industry is trading at a discount to its U.S. peers. There are other similar ones to own as well. It is good but he wants to see a couple of quarters with profitability.
Jordan ZinbergJordan Zinberg
No
Unlock Rating
$0.385

Stock price when the opinion was issued

Healthcare
PAST TOP PICK

CloudMD(DOC-X)

Jun 06, 2022
(A Top Pick Jun 23/21, Down 71%) Fastest growing health technology provider. Sector had been hit very hard with market selloff. Recently signed large contract with Sunlife. Process integrating large number of acquisitions. Recent CEO, Chairman and management resignations is cause for concern.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Owned
Unlock Rating
$0.520

Stock price when the opinion was issued

Healthcare
PAST TOP PICK

CloudMD(DOC-X)

Jun 01, 2022
(A Top Pick Jun 29/21, Down 77%) Brutal in the small cap area. Still likes it, but got stopped out. Beat expectations, business doing well. Moving forward with plans. This is why it's important to use stops, especially with small caps.
Bruce Campbell (2)Bruce Campbell (2)
No
Unlock Rating
$0.500

Stock price when the opinion was issued

Healthcare
BUY

CloudMD(DOC-X)

Mar 29, 2022
A fast-growing telehealth company and are pushing hard into enterprise health solutions by offering a one-stop patient approach to the primary care and mental health sectors. They are integrating several acquisitions. They are guiding to an EBITDA of $10 million this year which they could surpass. This sector has been almost left for dead, but the digital revolution in health has just begun so now is the time to enter it.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Owned
Unlock Rating
$0.820

Stock price when the opinion was issued

Healthcare
BUY

CloudMD(DOC-X)

Feb 25, 2022
One of the fastest healthcare technology companies. Expanding into enterprise health solutions space. Expecting strong financial results in 2022. Low stock price presenting good buying opportunity.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Owned
Unlock Rating
$0.680

Stock price when the opinion was issued

Healthcare
STRONG BUY

CloudMD(DOC-X)

Dec 13, 2021
One of two he owns in the health care sector. Digitization within health care has only just begun. The last quarter beat expectations. They announced a large deal with Sun Life on mental health coaching. This alone could be $40 million in annual revenues. Things are going in the right direction and will exceed expectations next year. A very good entry point here.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Owned
Unlock Rating
$1.160

Stock price when the opinion was issued

Healthcare
BUY

CloudMD(DOC-X)

Nov 09, 2021
Pre-announced today that revenues will be higher than forecast. Encouraging, as there's significant organic growth in addition to acquisitions. Likes the strategy. Will probably be one of the few telehealth winners. Lots of strings to their bow. Good time to buy. Sky's the limit on target prices for this sector. Good long-term hold.
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Unknown
Unlock Rating
$1.650

Stock price when the opinion was issued

Healthcare
BUY ON WEAKNESS

CloudMD(DOC-X)

Oct 15, 2021
Small caps have seen some correction, but the underlying fundamentals are growing. The business continues to move forward. What was considered telemedicine has now extended out to more services, such as employer plans. Top line growth is around 10% per quarter. They are profitable and has large cash positions to make acquisitions. Trading at half the valuation of WELL.
Bruce Campbell (2)Bruce Campbell (2)
No
Unlock Rating
$1.440

Stock price when the opinion was issued

Healthcare
BUY

CloudMD(DOC-X)

Oct 06, 2021
Exciting play on telemedicine. Entire sector is pricey, but good upside opportunity if the trends continue. The whole concept makes a lot of sense. Good sector to have some exposure to. He owns a small position.
Alex RuusAlex Ruus
Owned
Unlock Rating
$1.420

Stock price when the opinion was issued

Healthcare
TOP PICK

CloudMD(DOC-X)

Sep 20, 2021
It is one of the fastest growing healthcare solutions providers. They made a series of very targeted acquisitions which they are integrating. A quality company with quality assets. (Analysts’ price target is $4.19)
Stephen Takacsy, B. Eng, MBAStephen Takacsy, B. Eng, MBA
Owned
Unlock Rating
$1.640

Stock price when the opinion was issued

Healthcare
BUY

CloudMD(DOC-X)

Aug 27, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenue grew by 461% year over year. However, EPS missed estimates. It is growing extremely fast and organic growth is forecasted to be driven by partner relationships. The balance sheet is growing rapidly and top-line growth should outpace operating expenses. Unlock Premium - Try 5i Free

Stockchase InsightsStockchase Insights
Unknown
Unlock Rating
$1.740

Stock price when the opinion was issued

Healthcare
Showing 1 to 15 of 28 entries
Next PageNext Page

CloudMD(DOC-X) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for CloudMD is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CloudMD(DOC-X) Frequently Asked Questions

What is CloudMD stock symbol?

CloudMD is a Canadian stock, trading under the symbol DOC-X on the TSX Venture Exchange (DOC-CV). It is usually referred to as TSXV:DOC or DOC-X

Is CloudMD a buy or a sell?

In the last year, there was no coverage of CloudMD published on Stockchase.

Is CloudMD a good investment or a top pick?

CloudMD was recommended as a Top Pick by on . Read the latest stock experts ratings for CloudMD.

Why is CloudMD stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CloudMD worth watching?

0 stock analysts on Stockchase covered CloudMD In the last year. It is a trending stock that is worth watching.

What is CloudMD stock price?

On 2024-07-10, CloudMD (DOC-X) stock closed at a price of $0.035.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

LDOS-N -3.19$149.36
LULU-Q -5.455$315.745
NVDA-Q -0.69$134.81
CRM-N -1.16$276.03
RDDT-N 0.81$105.43

Today's Top Picks

SHOP-T 0.77$148.28
SU-T -0.49$48.88
ATD-T 0.21$72.96
CNQ-T -0.5$42.55
GOOG-Q -0.6$173.38

Popular Articles

Latest Sell Signals

TXN-Q 0.91$184.15
VOD-Q -0.11$10.39
ARM-Q 1.58$135.54
BCE-T -0.4$29.27
IVN-T -0.2$11.09

Most Recent Experts

Andrew Pyle

Andrew Pyle

The Pyle Group, Scotia Wealth Mgt.

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Martin Cobb, ASIP

Martin Cobb, ASIP

Lorne Steinberg Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica